10 các kết quả
FIELD OF THE INVENTION
The present invention is directed to a method for treating prostate cancer by administering collagenase alone or in combination with a glycosidase, a protease, a nuclease, a lipase, an esterase, a streptokinase, or a combination thereof. A typical embodiment includes
FIELD OF THE INVENTION
The present invention is directed to a method for treating prostate cancer by administering collagenase alone or in combination with a glycosidase, a protease, a nuclease, a lipase, an esterase, a streptokinase, or a combination thereof. A typical embodiment includes
COPYRIGHT NOTIFICATION
Pursuant to 37 C.F.R. .sctn.1.71(e), Applicants note that a portion of this disclosure contains material which is subject to copyright protection. The copyright owner has no objection to the facsimile reproduction by anyone of the patent document or patent disclosure, as it
FIELD OF THE INVENTION
The present invention relates to methods of prevention, treatment or alleviation of cachexia and other wasting syndromes or conditions of loss of weight and/or muscle atrophy by modulation, including inhibition, of lipase, particularly adipose triglyceride lipase (ATGL). The
TECHNICAL FIELD OF THE INVENTION
This invention is related to the area of oncology. In particular, it relates to treatment of tumors which enhance the selective toxicity of anti-cancer agents.
BACKGROUND OF THE INVENTION
There is no dearth of drugs that can kill cancer cells. The challenge is
TECHNICAL FIELD OF THE INVENTION
This invention is related to the area of oncology. In particular, it relates to treatment of tumors which enhance the selective toxicity of anti-cancer agents.
BACKGROUND OF THE INVENTION
There is no dearth of drugs that can kill cancer cells. The challenge is
TECHNICAL FIELD OF THE INVENTION
This invention is related to the area of oncology. In particular, it relates to treatment of tumors which enhance the selective toxicity of anti-cancer agents.
BACKGROUND OF THE INVENTION
There is no dearth of drugs that can kill cancer cells. The challenge is
BACKGROUND
Cannabinoid receptors, CB1 and CB2, are part of the endocannabinoid system (ECS), which consists of cannabinoid receptors, endogenous endocannabinoids anandamide (AEA) and 2-arachindonoylglycerol (2-AG) and the hydrolytic enzymes fatty acid amide hydrolase (FAAH) and monoacylglycerol
The present invention relates to methods for releasing an agent under pre-determined conditions. for example at a predetermined site or in the presence of a pre-determined material. and in particular for releasing an agent for therapeutic. diagnostic or investigative purposes The invention further
TECHNICAL FIELD
The present invention relates to a novel resveratrol polymerization compound or a pharmaceutically acceptable salt thereof and a method for manufacturing the same and relates to foods, pharmaceutical agents, quasi drugs, or cosmetics containing the resveratrol polymerization compound